“Gastroesophageal Reflux Disease market”
The Gastroesophageal Reflux Disease market growth is driven by factors like increase in the prevalence of Gastroesophageal Reflux Disease, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Gastroesophageal Reflux Disease market report also offers comprehensive insights into the Gastroesophageal Reflux Disease market size, share, Gastroesophageal Reflux Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Gastroesophageal Reflux Disease market size growth forward.
Some of the key highlights from the Gastroesophageal Reflux Disease Market Insights Report:
-
Several key pharmaceutical companies, including ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others, are developing novel products to improve the Gastroesophageal Reflux Disease treatment outlook.
-
In July 2024, Phathom Pharmaceuticals obtained an expanded indication for its acid suppression medication. The FDA approved the inclusion of heartburn relief associated with non-erosive gastroesophageal reflux disease in Voquezna’s label.
-
In November 2023, the FDA approved VOQUEZNA (vonoprazan) tablets in 10 mg and 20 mg dosages, a pioneering potassium-competitive acid blocker (PCAB), as a new treatment option for adults. This medication is indicated for healing all grades of Erosive Esophagitis, also known as Erosive GERD, as well as for maintaining healing and relieving heartburn associated with Erosive GERD.
-
In May 2023, Phathom Pharmaceuticals resubmitted its New Drug Application to the FDA for vonoprazan, seeking approval for the treatment of erosive gastroesophageal reflux disease (GERD), also known as erosive esophagitis.
-
In June 2022, Zydus Lifesciences received FDA approval to market Famotidine tablets in 20mg and 40mg strengths. Famotidine, a histamine H2 receptor blocker, works by reducing stomach acid and is used to relieve and prevent heartburn and other symptoms of acid reflux.
-
Several pharmaceutical companies, including Cinclus Pharma, Braintree (part of Sebela Pharmaceuticals), and N-Zyme Biomedical Inc., are actively researching and developing new therapies to meet the unmet needs of GERD patients.
-
As per DelveInsight analysis, the Gastroesophageal Reflux Disease market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Gastroesophageal Reflux Disease Market Landscape
Gastroesophageal Reflux Disease Overview
Gastroesophageal reflux disease (GERD) is a chronic condition in which stomach contents, including acid and bile, flow back into the esophagus, causing symptoms like heartburn, regurgitation, and chest pain. It commonly results from a dysfunction of the lower esophageal sphincter (LES), which typically prevents gastric contents from entering the esophagus. Contributing factors include hiatal hernia, poor esophageal motility, obesity, and certain dietary habits, such as consuming spicy or fatty foods, caffeine, and alcohol. GERD can present as non-erosive reflux disease (NERD), where no visible damage occurs to the esophageal lining, or as erosive esophagitis, which involves inflammation and damage to the esophageal tissue.
Symptoms of GERD can vary in intensity and may include heartburn (a burning sensation in the chest, often aggravated by eating or lying down), regurgitation of acid into the mouth, difficulty swallowing (dysphagia), chest pain, and chronic cough. These symptoms can negatively affect quality of life and may lead to complications such as esophageal strictures, Barrett’s esophagus, and esophageal adenocarcinoma if not treated.
Do you know the treatment paradigms for different countries? Download our Gastroesophageal Reflux Disease Market Sample Report
Gastroesophageal Reflux Disease Epidemiology Insights
-
Our analysis shows that the prevalence of GERD in North America ranges from 18% to 28%, while in Europe, it varies from 9% to 26%, indicating a considerable disease burden across both regions.
-
We also found that females have a higher prevalence of GERD compared to males, suggesting a gender disparity in the occurrence of the condition. This highlights the importance of addressing gender-specific factors in GERD management and treatment. The higher prevalence in females may be due to factors such as hormonal changes, differences in esophageal motility, and anatomical differences.
-
Additionally, our findings indicate that the age group of 50-59 years has the highest prevalence of GERD, while those aged 70 and above have the lowest. This trend could be linked to age-related changes in gastrointestinal function, lifestyle factors, and the presence of comorbidities in older individuals.
Gastroesophageal Reflux Disease Epidemiology Segmentation
DelveInsight’s Gastroesophageal Reflux Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Gastroesophageal Reflux Disease historical patient pools and forecasted Gastroesophageal Reflux Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Gastroesophageal Reflux Disease Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
-
Gastroesophageal Reflux Disease Prevalence
-
Age-Specific Gastroesophageal Reflux Disease Prevalence
-
Gender-Specific Gastroesophageal Reflux Disease Prevalence
-
Diagnosed and Treatable Cases of Gastroesophageal Reflux Disease
Visit for more @ Gastroesophageal Reflux Disease Epidemiological Insights
Gastroesophageal Reflux Disease Market Insights:
-
Several major companies, including Alexion Pharmaceuticals, Novartis, and Roche, are leading the Gastroesophageal Reflux Disease (aHUS) treatment landscape. The market details, broken down by country and therapy, are outlined below.
-
According to DelveInsight’s patient-based forecasting model, the total aHUS market size in the 7MM was approximately USD 1,300 million in 2023, and significant growth is anticipated during the forecast period due to the introduction of new therapies.
-
In 2023, the United States accounted for the largest share of the aHUS market in the 7MM, approximately 70%, followed by Germany and France.
-
Among emerging therapies for aHUS, Novartis’ iptacopan and Roche’s crovalimab are expected to play a pivotal role in transforming the market. By 2034, iptacopan is projected to generate the highest revenue among emerging treatments, with nearly USD 100 million expected in the EU4 and the UK.
Gastroesophageal Reflux Disease Market Outlook
The management of GERD is divided into five stages: four stages of medical management and one stage involving surgical intervention. The goal of treatment is to reduce esophageal exposure to reflux, alleviate symptoms, heal the esophagus, prevent complications, and maintain remission. Most GERD patients can manage symptoms and promote healing through lifestyle changes and drug therapy without requiring surgery. Surgery is considered for those with severe symptoms, erosive esophagitis, or disease complications despite adequate medication.
Lifestyle changes, such as elevating the head of the bed, reducing fat intake, quitting smoking, limiting alcohol, losing weight, and avoiding large meals and certain foods, are essential throughout treatment.
For mild symptoms, periodic drug therapy is often necessary, using antacids, alginic acid, or over-the-counter H2-receptor blockers. Antacids offer quick symptom relief by neutralizing gastric acid but are not used alone for esophageal healing due to their high dosage requirements. Alginic acid forms a mechanical barrier over the refluxate, protecting the esophagus. H2-receptor blockers provide longer relief, making them more suitable for symptom prevention.
For moderate to severe symptoms, scheduled pharmacologic therapy is required. Proton pump inhibitors (PPIs), such as Dexilant (dexlansoprazole), are used to suppress gastric acid, heal esophagitis, and maintain remission.
Surgery may be needed if medical therapy fails or complications arise, such as large hiatal hernia, Barrett’s esophagus, severe esophagitis, recurrent strictures, or significant pulmonary symptoms. Noncompliance, financial barriers, and relapse of symptoms can also contribute to the need for surgery.
Gastroesophageal Reflux Disease Marketed Drugs
Gastroesophageal Reflux Disease Emerging Drugs
Gastroesophageal Reflux Disease Key Companies
-
ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others
For more information, visit Gastroesophageal Reflux Disease Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Gastroesophageal Reflux Disease Market Report:
-
11 Years Forecast
-
7MM Coverage
-
Descriptive overview of Gastroesophageal Reflux Disease, causes, signs and symptoms, diagnosis, treatment
-
Comprehensive insight into Gastroesophageal Reflux Disease epidemiology in the 7MM
-
Gastroesophageal Reflux Disease marketed and emerging therapies
-
Gastroesophageal Reflux Disease companies
-
Gastroesophageal Reflux Disease market drivers and barriers
Table of Contents:
1 Gastroesophageal Reflux Disease Market Key Comprehensive Insights
2 Gastroesophageal Reflux Disease Market Report Introduction
3 Competitive Intelligence Analysis for Gastroesophageal Reflux Disease
4 Gastroesophageal Reflux Disease Market Analysis Overview at a Glance
5 Executive Summary of Gastroesophageal Reflux Disease
6 Gastroesophageal Reflux Disease Epidemiology and Market Methodology
7 Gastroesophageal Reflux Disease Epidemiology and Patient Population
8 Gastroesophageal Reflux Disease Patient Journey
9 Gastroesophageal Reflux Disease Treatment Algorithm, Gastroesophageal Reflux Disease Current Treatment, and Medical Practices
10 Key Endpoints in Gastroesophageal Reflux Disease Clinical Trials
11 Gastroesophageal Reflux Disease Marketed Therapies
12 Gastroesophageal Reflux Disease Emerging Therapies
13 Gastroesophageal Reflux Disease: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Gastroesophageal Reflux Disease
16 Gastroesophageal Reflux Disease Market Key Opinion Leaders Reviews
18 Gastroesophageal Reflux Disease Market Drivers
19 Gastroesophageal Reflux Disease Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Gastroesophageal Reflux Disease Epidemiology 2034
DelveInsight’s “Gastroesophageal Reflux Disease – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Gastroesophageal Reflux Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Gastroesophageal Reflux Disease Pipeline 2024
“Gastroesophageal Reflux Disease Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Gastroesophageal Reflux Disease market. A detailed picture of the Gastroesophageal Reflux Disease pipeline landscape is provided, which includes the disease overview and Gastroesophageal Reflux Disease treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Gastroesophageal Reflux Disease Market Expected to rise, 2034 | ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno
